Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with hepatitis C

ABSTRACT

Background and aim: H.C.V. is prevalent in H.D. patients with variable rates from 1-4% in Japan and UK, 7-10% in U.S., 10-15 in Central Europe up to 60-80% in South America and Middle East countries. These patients experience more side-effects with anti-H.C.V. treatment. The aim of this study was to evaluate the efficacy and tolerability of pegylated interferon [PEG-IFN] alpha-2a in chronic hemodialysis patients with chronic hepatitis C infection